TY - JOUR
T1 - Current concepts on antiplatelet therapy
T2 - Focus on the novel thienopyridine and non-thienopyridine agents
AU - Bhindi, R.
AU - Testa, L.
AU - Biondi Zoccai, G. G L
AU - Valgimigli, M.
AU - Latini, R. A.
AU - Pizzocri, S.
AU - Lanotte, S.
AU - Laudisa, M. L.
AU - Brambilla, N.
AU - Ward, M. R.
AU - Figtree, G. A.
AU - Bedogni, F.
PY - 2010
Y1 - 2010
N2 - Thienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological feature, particularly myocardial infarction. Ticlopidine, the first of the class introduced to clinical practice, was soon challenged and almost completely replaced by clopidogrel for its better tolerability. More recently, prasugrel and ticagrelor have been shown to provide a more powerful antiplatelet action compared to clopidogrel but at a cost of higher risk of bleeding complications. Cangrelor, a molecule very similar to ticagrelor, is currently being evaluated against clopidogrel. Considering the key balance of ischemic protection and bleeding risk, this paper discusses the background to the development of prasugrel, ticagrelor, and cangrelor and aims to characterise their risk-benefit profile and possible implementation in daily practice.
AB - Thienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological feature, particularly myocardial infarction. Ticlopidine, the first of the class introduced to clinical practice, was soon challenged and almost completely replaced by clopidogrel for its better tolerability. More recently, prasugrel and ticagrelor have been shown to provide a more powerful antiplatelet action compared to clopidogrel but at a cost of higher risk of bleeding complications. Cangrelor, a molecule very similar to ticagrelor, is currently being evaluated against clopidogrel. Considering the key balance of ischemic protection and bleeding risk, this paper discusses the background to the development of prasugrel, ticagrelor, and cangrelor and aims to characterise their risk-benefit profile and possible implementation in daily practice.
UR - http://www.scopus.com/inward/record.url?scp=79251574325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79251574325&partnerID=8YFLogxK
U2 - 10.1155/2010/595934
DO - 10.1155/2010/595934
M3 - Article
C2 - 21151515
AN - SCOPUS:79251574325
VL - 2010
JO - Advances in Hematology
JF - Advances in Hematology
SN - 1687-9104
M1 - 595934
ER -